President Donald Trump will deliver his first major speech on drug prices on April 26; a recent Medicare Payment Advisory Commission proposal would cut Medicare payment rates by 30% for some services at hospital-affiliated free-standing emergency departments; nursing homes routinely turn away patients seeking care if they are using medication-assisted treatment to treat substance use disorder for opioids.
President Donald Trump will deliver his first major speech about drug prices on April 26, Politico reported. Based on his fiscal 2019 budget request, he could advocate for Medicare and Medicaid demonstrations to test new ways of paying for drugs on a smaller scale, like allowing some states to try negotiating drug costs in Medicaid. He is unlikely to call for the sort of actions he did when he was a candidate, like allowing the government to negotiate the cost of drugs for Medicare.
A recent Medicare Payment Advisory Commission (MedPAC) proposal would cut Medicare payment rates by 30% for some services at hospital-affiliated free-standing emergency departments (EDs) that are located within 6 miles of an on-campus hospital ED, Kaiser Health News reported. Free-standing EDs have been growing and now number more than 500. The proposal is spurred by concerns that MedPAC’s payment for services at these facilities is higher than it should be since the patients who visit them are sometimes not as severely injured or ill as those at hospital facilities.
Nursing homes routinely turn away patients seeking care if they are using medication-assisted treatment (MAT) to treat substance use disorder for opioids—a practice that legal experts say violates the Americans with Disabilities Act, STAT reported. After hospital discharge, many patients require further nursing care. But STAT has found that many nursing facilities refuse to accept such patients, often because of stigma, gaps in training, and the widespread misconception that abstinence is superior to medications for treating addiction. Nursing home staff may be unfamiliarity with MAT. Facilities may not have a clinician on staff licensed to prescribe buprenorphine and may be unaware that the patient’s primary care doctor often can continue to provide the medicine.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars
November 21st 2023Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Read More
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen
Therapists’ Perspectives on Access to Telemental Health Among Medicaid-Enrolled Youth
November 10th 2023This qualitative study elucidates therapists’ perspectives on barriers to and facilitators of access to telemental health among Medicaid-enrolled youth served by a large safety-net organization.
Read More